# COVID-19 Treatment of Severe Acute Respiratory Syndrome With Veru-111

> **NCT04388826** · PHASE2 · COMPLETED · sponsor: **Veru Inc.** · enrollment: 39 (actual)

## Conditions studied

- Respiratory Distress Syndrome, Adult

## Interventions

- **DRUG:** Veru-111

## Key facts

- **NCT ID:** NCT04388826
- **Lead sponsor:** Veru Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-06-18
- **Primary completion:** 2020-12-18
- **Final completion:** 2021-08-13
- **Target enrollment:** 39 (ACTUAL)
- **Last updated:** 2022-10-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04388826

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04388826, "COVID-19 Treatment of Severe Acute Respiratory Syndrome With Veru-111". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT04388826. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*